Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies
Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a receptor tyrosine kinase, presents a promising target for breast cancer therapy du...
Saved in:
| Main Authors: | Emeka Eze Joshua Iweala, Doris Nnenna Amuji, Abimbola Mary Oluwajembola, Eziuche Amadike Ugbogu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257124000312 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities
(2025 Version)
by: Jun CHEN, et al.
Published: (2025-02-01) -
Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01) -
Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance
by: Isaac Micallef, et al.
Published: (2024-12-01) -
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors
by: Dongna Zhang, et al.
Published: (2024-12-01) -
Exosomal long non-coding RNAs in gastrointestinal cancer: chemoresistance mediators and therapeutic targets
by: Chenhe Li, et al.
Published: (2025-08-01)